{"protocolSection": {"identificationModule": {"nctId": "NCT01181674", "orgStudyIdInfo": {"id": "REMIT Pilot"}, "secondaryIdInfos": [{"id": "Control # 139433, 143584", "type": "OTHER", "domain": "Health Canada"}, {"id": "10-346", "type": "OTHER", "domain": "Hamilton Health Sciences Research Ethics Board"}], "organization": {"fullName": "Population Health Research Institute", "class": "OTHER"}, "briefTitle": "Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)", "officialTitle": "Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial"}, "statusModule": {"statusVerifiedDate": "2020-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01"}, "primaryCompletionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-08-11", "studyFirstSubmitQcDate": "2010-08-12", "studyFirstPostDateStruct": {"date": "2010-08-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-04-06", "resultsFirstSubmitQcDate": "2020-05-10", "resultsFirstPostDateStruct": {"date": "2020-05-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-05-10", "lastUpdatePostDateStruct": {"date": "2020-05-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr. Hertzel Gerstein", "investigatorTitle": "Director, Division of Endocrinology and Metabolism, McMaster University", "investigatorAffiliation": "Population Health Research Institute"}, "leadSponsor": {"name": "Population Health Research Institute", "class": "OTHER"}, "collaborators": [{"name": "Hamilton Health Sciences Corporation", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes mellitus when compared to standard diabetes care.", "detailedDescription": "This is a pilot trial of 125 patients allocated to either usual care (1/3), 2 months or 4 months of intensive lifestyle and pharmacotherapy followed by cessation of all drug therapy."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes", "Insulin", "Glargine", "Metformin", "Acarbose", "Diet", "Exercise", "Lifestyle"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 83, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group 1 (short)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin glargine", "Drug: metformin", "Drug: acarbose", "Behavioral: lifestyle therapy"]}, {"label": "Group 2 (long)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin glargine", "Drug: metformin", "Drug: acarbose", "Behavioral: lifestyle therapy"]}, {"label": "Standard care", "type": "OTHER", "interventionNames": ["Other: Standard glycemic care"]}], "interventions": [{"type": "DRUG", "name": "insulin glargine", "description": "sc injection", "armGroupLabels": ["Group 1 (short)"]}, {"type": "DRUG", "name": "metformin", "description": "oral administration", "armGroupLabels": ["Group 1 (short)"]}, {"type": "DRUG", "name": "acarbose", "description": "oral administration", "armGroupLabels": ["Group 1 (short)"]}, {"type": "BEHAVIORAL", "name": "lifestyle therapy", "description": "diet and exercise", "armGroupLabels": ["Group 1 (short)"]}, {"type": "DRUG", "name": "insulin glargine", "description": "sc injection", "armGroupLabels": ["Group 2 (long)"]}, {"type": "DRUG", "name": "metformin", "description": "oral administration", "armGroupLabels": ["Group 2 (long)"]}, {"type": "DRUG", "name": "acarbose", "description": "oral administration", "armGroupLabels": ["Group 2 (long)"]}, {"type": "BEHAVIORAL", "name": "lifestyle therapy", "description": "diet and exercise", "armGroupLabels": ["Group 2 (long)"]}, {"type": "OTHER", "name": "Standard glycemic care", "description": "as informed by the current clinical practice guidelines", "armGroupLabels": ["Standard care"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Normoglycemia on Therapy", "description": "1. Percentage of participants achieving normoglycemia on therapy in the experimental group 1 compared to the control group.\n2. Percentage of participants achieving normoglycemia on therapy in the experimental group 2 compared to the control group.\n\nNormoglycemia on therapy is defined as a mean fasting capillary blood glucose \\</=5.4 mmol/L and a mean 2-hour pc blood glucose \\</=6.8 mmol/L on 2 seven-point glucose profiles.", "timeFrame": "(1) 8 weeks and (2) 16 weeks"}], "secondaryOutcomes": [{"measure": "1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.", "description": "Normal glucose tolerance is defined as a fasting plasma glucose \\<6.1 mmol/L and a 2-hour pc plasma glucose \\<7.8 mmol/L on a 75 g oral glucose tolerance test off diabetes drugs.", "timeFrame": "(1) 20 weeks and (2) 28 weeks"}, {"measure": "Percentage of Participants With Normal Fasting Plasma Glucose", "description": "Normal fasting plasma glucose is defined as \\<6.1 mmol/L.", "timeFrame": "52 weeks"}, {"measure": "Change in Fasting Plasma Glucose From Baseline", "timeFrame": "Baseline and 52 weeks"}, {"measure": "HbA1C", "timeFrame": "8, 20, 28 and 52 weeks"}, {"measure": "Change in Weight From Baseline", "timeFrame": "Baseline, 8, 20, 28 and 52 weeks"}, {"measure": "Number of Participants With Symptomatic Hypoglycemic Episodes", "timeFrame": "52 weeks"}, {"measure": "Number of Participants With Severe Hypoglycemic Episodes", "timeFrame": "52 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. men and women 30-80 years of age inclusive\n2. type 2 diabetes mellitus diagnosed by a physician within 3 years prior to patient enrollment\n3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks prior to screening and randomization\n4. HbA1C \u2264 8.5% on no oral hypoglycemic agents or HbA1C \u2264 7.5% on 1 agent or on half-maximal doses of 2 agents\n5. body mass index \u2265 23 kg/m2\n6. a negative pregnancy test and an agreement to use a reliable method of birth control for the duration of the trial in all females with childbearing potential\n7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG)\n8. ability and willingness to self-inject insulin\n9. provision of informed consent.\n\nExclusion Criteria:\n\n1. current use of insulin therapy\n2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance\n3. renal dysfunction as evidenced by serum creatinine (Cr) \u2265 124 \u03bcmol/l\n4. history of lactic acidosis or diabetic ketoacidosis\n5. active liver disease or elevated alanine transferase (ALT) levels \u2265 2.5 times upper limit of normal at the time of enrollment\n6. history of inflammatory bowel disease, colonic ulcers, recent or significant bowel surgery, or predisposition to bowel obstruction\n7. cardiovascular disease including any of:\n\n   * systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>105 mmHg\n   * peripheral vascular disease\n   * left bundle branch block or third degree AV block\n   * tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate\n   * stenotic valvular heart disease\n   * cardiomyopathy\n   * history of heart failure\n   * history of aortic dissection\n   * documented history of angina or coronary artery disease\n   * history of stroke or transient ischemic attack\n8. pulmonary disease with dependence on oxygen\n9. history of any disease requiring intermittent or continuous systemic glucocorticoid treatment\n10. history of any major illness with a life expectancy of \\<3 years\n11. history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity\n12. any history of excessive alcohol intake, acute or chronic\n13. known hypersensitivity to metformin, acarbose, or insulin glargine.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Hertzel Gerstein, MD", "affiliation": "Population Health Research Institute", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Natalia McInnes (nee Yakubovich), MD", "affiliation": "Population Health Research Institute", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "McMaster University Medical Centre, Diabetes Care and Research Program", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}]}, "referencesModule": {"references": [{"pmid": "28324049", "type": "RESULT", "citation": "McInnes N, Smith A, Otto R, Vandermey J, Punthakee Z, Sherifali D, Balasubramanian K, Hall S, Gerstein HC. Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. J Clin Endocrinol Metab. 2017 May 1;102(5):1596-1605. doi: 10.1210/jc.2016-3373."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "FG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "FG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "28"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "comment": "28 included in analyses", "numSubjects": "26"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "BG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "BG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "83"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.1", "spread": "9.2"}, {"groupId": "BG001", "value": "57.9", "spread": "10.5"}, {"groupId": "BG002", "value": "58.2", "spread": "11.1"}, {"groupId": "BG003", "value": "57.1", "spread": "10.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "43"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "40"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "25"}, {"groupId": "BG003", "value": "73"}]}]}, {"title": "Non-Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "10"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "83"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Normoglycemia on Therapy", "description": "1. Percentage of participants achieving normoglycemia on therapy in the experimental group 1 compared to the control group.\n2. Percentage of participants achieving normoglycemia on therapy in the experimental group 2 compared to the control group.\n\nNormoglycemia on therapy is defined as a mean fasting capillary blood glucose \\</=5.4 mmol/L and a mean 2-hour pc blood glucose \\</=6.8 mmol/L on 2 seven-point glucose profiles.", "populationDescription": "Primary outcome (1) is reported in Experimental Group 1 and Standard care at 8 weeks. Primary outcome (2) is reported in experimental Group 2 and Standard care at 16 weeks.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "(1) 8 weeks and (2) 16 weeks", "groups": [{"id": "OG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "28"}]}], "classes": [{"title": "Group 1 and Standard care at 8 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Group 2 and Standard care at 16 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.", "description": "Normal glucose tolerance is defined as a fasting plasma glucose \\<6.1 mmol/L and a 2-hour pc plasma glucose \\<7.8 mmol/L on a 75 g oral glucose tolerance test off diabetes drugs.", "populationDescription": "Outcome (1) is reported in Experimental Group 1 and Standard care at 20 weeks. Outcome (2) is reported in experimental Group 2 and Standard care at 28 weeks.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "(1) 20 weeks and (2) 28 weeks", "groups": [{"id": "OG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "28"}]}], "classes": [{"title": "Group 1 and Standard care at 20 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Group 2 and Standard care at 28 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Normal Fasting Plasma Glucose", "description": "Normal fasting plasma glucose is defined as \\<6.1 mmol/L.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose From Baseline", "populationDescription": "FPG was not available for some participants at 52 weeks.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline and 52 weeks", "groups": [{"id": "OG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23", "spread": "0.96"}, {"groupId": "OG001", "value": "-0.64", "spread": "1.38"}, {"groupId": "OG002", "value": "0.05", "spread": "1.02"}]}]}]}, {"type": "SECONDARY", "title": "HbA1C", "populationDescription": "Some participants did not provide HbA1C values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent", "timeFrame": "8, 20, 28 and 52 weeks", "groups": [{"id": "OG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "25"}]}], "classes": [{"title": "8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.1", "spread": "0.5"}, {"groupId": "OG001", "value": "6.0", "spread": "0.4"}, {"groupId": "OG002", "value": "6.6", "spread": "0.7"}]}]}, {"title": "20 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.2", "spread": "0.4"}, {"groupId": "OG001", "value": "6.1", "spread": "0.3"}, {"groupId": "OG002", "value": "6.6", "spread": "0.7"}]}]}, {"title": "28 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.5", "spread": "0.8"}, {"groupId": "OG001", "value": "6.4", "spread": "0.5"}, {"groupId": "OG002", "value": "6.6", "spread": "0.7"}]}]}, {"title": "52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.4", "spread": "0.8"}, {"groupId": "OG001", "value": "6.7", "spread": "0.7"}, {"groupId": "OG002", "value": "6.5", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Change in Weight From Baseline", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Baseline, 8, 20, 28 and 52 weeks", "groups": [{"id": "OG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "25"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.5", "spread": "23.3"}, {"groupId": "OG001", "value": "95.3", "spread": "15.2"}, {"groupId": "OG002", "value": "89.3", "spread": "14.6"}]}]}, {"title": "8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.3", "spread": "21.8"}, {"groupId": "OG001", "value": "92.4", "spread": "15.0"}, {"groupId": "OG002", "value": "87.1", "spread": "14.1"}]}]}, {"title": "20 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.8", "spread": "21.1"}, {"groupId": "OG001", "value": "90.5", "spread": "14.8"}, {"groupId": "OG002", "value": "86.3", "spread": "13.5"}]}]}, {"title": "28 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.3", "spread": "20.6"}, {"groupId": "OG001", "value": "91.7", "spread": "15.2"}, {"groupId": "OG002", "value": "86.1", "spread": "13.5"}]}]}, {"title": "52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "96.6", "spread": "21.7"}, {"groupId": "OG001", "value": "93.8", "spread": "16.4"}, {"groupId": "OG002", "value": "86.5", "spread": "14.6"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Symptomatic Hypoglycemic Episodes", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Severe Hypoglycemic Episodes", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise"}, {"id": "OG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "52 weeks", "eventGroups": [{"id": "EG000", "title": "Group 1 (Short)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise", "deathsNumAffected": 0, "deathsNumAtRisk": 28, "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 3, "otherNumAtRisk": 28}, {"id": "EG001", "title": "Group 2 (Long)", "description": "insulin glargine: sc injection\n\nmetformin: oral administration\n\nacarbose: oral administration\n\nlifestyle therapy: diet and exercise", "deathsNumAffected": 0, "deathsNumAtRisk": 27, "seriousNumAffected": 0, "seriousNumAtRisk": 27, "otherNumAffected": 1, "otherNumAtRisk": 27}, {"id": "EG002", "title": "Standard Care", "description": "Standard glycemic care: as informed by the current clinical practice guidelines", "deathsNumAffected": 0, "deathsNumAtRisk": 28, "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 3, "otherNumAtRisk": 28}], "otherEvents": [{"term": "Chest pain", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}, {"term": "Fracture", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 28}]}, {"term": "Motor vehicle accident", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Natalia McInnes (nee Yakubovich)", "organization": "McMaster University", "email": "natalia.mcinnes@mcmaster.ca", "phone": "905-521-2100"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000020909", "term": "Acarbose"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065089", "term": "Glycoside Hydrolase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M22644", "name": "Acarbose", "asFound": "Thyroidectomy", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M5557", "name": "Cardiac Glycosides", "relevance": "LOW"}, {"id": "M30447", "name": "Glycoside Hydrolase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}